CBIO analyst estimates

Crescent Biopharma (CBIO) analyst ratings, the average price target and its range, and every firm's latest call.

CBIO analyst ratings and price targets

DateFirmCallTarget
Oct 19, 2026UBSH.C. Wainwright Reiterates Buy Rating on Crescent Biopharma Inc (CBIO)$36.00
Oct 6, 2026H.C. WainwrightCrescent Biopharma upgraded to Buy from Neutral at H.C. Wainwright$36.00
Feb 26, 2026Stifel NicolausCrescent Biopharma Inc (CBIO) PT Lowered to $29 at Stifel$29.00
Jan 28, 2026Piper SandlerCrescent Biopharma initiated with an Overweight at Piper Sandler$35.00
Jan 21, 2026GuggenheimCrescent Biopharma initiated with a Buy at Guggenheim$35.00
Dec 4, 2025Stifel NicolausCrescent Biopharma price target raised to $32 from $28 at Stifel$32.00
Aug 25, 2025JefferiesCrescent Biopharma initiated with a Buy at Jefferies$26.00